N-003 is a product under development. It is not approved for commercialisation.
© 2016 — Noorik Biopharmaceuticals, Switzerland
Our focus is Acute Kidney Injury, an unmet medical need... at present.
N-003 is a clinical stage development project of a well-characterised substance targeting renal vasoconstriction, the cause of selected forms of Acute Kidney Injury. By repurposing or reprofiling this active substance in a new indication, our development path is focused and shorter. Read more
It is a common cause of kidney failure and in many cases a condition leading to the need for dialysis or transplantation. Some forms of Acute Kidney Injury are secondary to ischemia, a temporary reduction or interruption of blood flow to the kidney.
An increase in renal vascular resistance is in many cases the cause and consequence of ischemia. Our two target indications are orphan diseases:
Delayed Graft Function, a complication of renal transplantation occurring frequently in the post-transplantation period when the transplanted kidney is of cadaveric origin. Read more
Hepatorenal Syndrome, a severe form of kidney failure in patients with advanced liver failure such as cirrhosis, and frequently leading to death. Read more
Noorik Biopharmaceuticals is a privately owned drug development company based in Basel, Switzerland.
Our focus is to address an unmet medical need at the crossroads of drug re-profiling and nephrology.
We outsource all development work which allows us to run
an efficient and lean organization.
N-003 is a product under development. It is not approved for commercialisation.
© 2016 — Noorik Biopharmaceuticals, Switzerland